Formoterol (Modulite), tiotropium and their combination in patients with acute exacerbation of chronic bronchitis: preliminary data Source: Eur Respir J 2005; 26: Suppl. 49, 285s Year: 2005
Formoterol Turbuhaler as reliever medication in patients with acute asthma Source: Eur Respir J 2006; 27: 735-741 Year: 2006
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Formoterol via turbuhaler (F) versus salbutamol via pressurized metered-dose inhaler (SB) in acute exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001
Addition of formoterol Turbuhaler® to budesonide Turbuhaler® increases the time to first severe exacerbation in long-term treatment of mild asthma: results from OPTIMA Source: Eur Respir J 2001; 18: Suppl. 33, 517s Year: 2001
The role of nebulised budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2007; 30: 399-400 Year: 2007
Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma Source: Eur Respir J, 57 (2) 2003064; 10.1183/13993003.03064-2020 Year: 2021
Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Clinical efficacy of nebulised budesonide in acute exacerbation of COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010
Improved lung function and symptom control with formoterol on demand in asthma Source: Eur Respir J 2006; 27: 504-510 Year: 2006
Aerosolized fluticasone propionate therapy in acute moderate exacerbations of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002
FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Inhaled formoterol in the treatment of acute asthma exacerbation at emergency room Source: Eur Respir J 2004; 24: Suppl. 48, 343s Year: 2004
Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001
A comparison of salmeterol xinafoate (SX) plus beclomethasone dipropionate (BDP) and theophylline (Theo) plus BDP in the treatment of moderate chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005
The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007